Lipid Metabolism Disorders: Clinical Trials

4,366 trials for Lipid Metabolism Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2849 completed, 502 unknown, 341 recruiting, 231 terminated. 1213 Not applicable, 737 Phase 3, 626 Phase 2, 548 Phase 1, 417 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable1213Completed 780, Unknown 181, Recruiting 99, Not yet recruiting 47, Active not recruiting 37, Terminated 33, Withdrawn 20, Enrolling by invitation 14, Suspended 2
Phase 3737Completed 551, Terminated 64, Unknown 41, Recruiting 30, Active not recruiting 22, Withdrawn 16, Not yet recruiting 10, Enrolling by invitation 3
Phase 2626Completed 436, Terminated 54, Unknown 39, Recruiting 30, Active not recruiting 25, Not yet recruiting 23, Withdrawn 14, Suspended 3, Enrolling by invitation 2
Phase 1548Completed 408, Terminated 30, Unknown 29, Recruiting 27, Active not recruiting 21, Not yet recruiting 19, Withdrawn 10, Enrolling by invitation 2, Suspended 2
Phase 4417Completed 283, Unknown 62, Terminated 26, Withdrawn 17, Recruiting 14, Not yet recruiting 7, Active not recruiting 5, Enrolling by invitation 2, Suspended 1
Early Phase 142Completed 20, Recruiting 9, Unknown 4, Active not recruiting 3, Not yet recruiting 3, Terminated 2, Enrolling by invitation 1

Follow Lipid Metabolism Disorders: new trials by email Literature Review of Lipid Metabolism Disorders trials Research Report on Lipid Metabolism Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Patient-engaged Development and Testing of Educational Content on Side Effects of Statins
Educational content on statin side effects - Dyslipidemia
Not applicableSuspendedWeill Medical College of Cornell University302028-09-012026-09-23
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
Lentiviral TYF-ARSA correction of patient's autologous HSCs - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-11-02
Direct Lentiviral Injection Gene Therapy for MLD
Intrathecal and intravenous LV gene therapy - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-05-312026-11-02
Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose
Pecan, Control - Nutrition, Healthy, Dyslipidemia
Not applicableNot yet recruitingUniversity of Georgia902027-03-012026-08-11
Coronary Artery Calcium (CAC) Testing in Primary Care
Our Practice Advisory (OPA) - ASCVD, ASCVD Management
Not applicableNot yet recruitingWeill Medical College of Cornell University202027-02-012026-10-15
PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis
Hyperlipidemia, Atherosclerotic Cardiovascular Disease (ASCVD)
Not yet recruitingFundación Santa Fe de Bogota1002027-02-012026-10-02
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia
Phase 4Not yet recruitingAmgen3082027-01-312026-09-21
A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion
Gaucher Disease
Not yet recruitingTakeda602027-01-312026-10-01
Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)
AZ-3102 - Gaucher Disease Type 3
Phase 2Not yet recruitingAzafaros B.V.202027-01-252026-11-12
Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial
Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase - GM1 Gangliosidoses, GM1 Gangliosidosis, Type I
Phase 1Not yet recruitingTippi Mackenzie52027-01-012026-08-31
RCT for the Chinese Medicine in Treating Hypercholesterolemia
Dachaihu Decoction combined Erzhiwan with variation, Placebo granules - Hypercholesterolemia
Phase 2Not yet recruitingChinese University of Hong Kong702027-01-012026-07-30
An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia
Hypercholesterolaemia, Familial Hypercholesterolaemia
Not yet recruitingFondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)25002027-01-012026-11-03
Lipid Management Gaps in Mexican Patients at High and Very High Cardiovascular Risk
Lipid-Lowering Therapy in Routine Clinical Practice - Dyslipidemias, Hypercholesterolemia
Not yet recruitingInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran16002027-01-012026-11-12
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
GD2, PSMA and CD276 CAR-T cells - Neuroblastoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002026-12-312026-10-30
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
Laroprovstat, Rosuvastatin 1, Rosuvastatin 2 - Hypercholesterolemia
Phase 3Not yet recruitingAstraZeneca2042026-12-212026-11-12
The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)
Venglustat, Imiglucerase - Gaucher's Disease Type III
Phase 3Not yet recruitingSanofi182026-12-112026-11-10
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis
Phase 2 / Phase 3Not yet recruitingAzafaros B.V.2182026-12-102026-10-21
Synbiotic as an Adjuvant Therapy for Dyslipidaemia and Gut Health
Synbiotic (LAB12 and SWEOAT® Bran), Oat-based Placebo - Dyslipidemia
Phase 2Not yet recruitingUniversiti Teknologi Mara1902026-12-022026-11-05
Germany on Target Registry
No study-assigned intervention - Myocardial Infarction (MI), Dyslipidemias
Not yet recruitingDeutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga100002026-12-012026-09-28
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)
PLX-200 - Lysosomal Storage Disorders, Sandhoff Disease
Phase 2Not yet recruitingPolaryx Therapeutics, Inc.242026-12-012026-07-31

Showing 20 of 4366. Sign in to see all of them.

Narrower conditions

Dyslipidemias (1202)  ·  Hypercholesterolemia (1135)  ·  Hyperlipidemias (847)  ·  Hypertension (623)  ·  Diabetes Mellitus (439)  ·  Obesity (412)  ·  Cardiovascular Diseases (374)  ·  Hypertriglyceridemia (316)  ·  Diabetes Mellitus, Type 2 (274)  ·  Fabry Disease (243)  ·  Hyperlipoproteinemia Type II (227)  ·  Metabolic Syndrome (219)  ·  Atherosclerosis (181)  ·  Gaucher Disease (176)

Broader conditions

Nutritional and Metabolic Diseases (4358)  ·  Metabolic Diseases (4281)  ·  Dyslipidemias (2210)  ·  Hyperlipidemias (1495)  ·  Vascular Diseases (1223)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1193)  ·  Genetic Diseases, Inborn (1149)  ·  Lipid Metabolism, Inborn Errors (1124)  ·  Metabolism, Inborn Errors (1096)  ·  Cardiovascular Diseases (1077)  ·  Pathological Conditions, Signs and Symptoms (873)  ·  Glucose Metabolism Disorders (865)  ·  Nervous System Diseases (770)  ·  Endocrine System Diseases (729)

Interventions

Atorvastatin (270)  ·  Ezetimibe (210)  ·  Rosuvastatin Calcium (194)  ·  Simvastatin (134)  ·  Fenofibrate (81)  ·  evolocumab (65)  ·  alirocumab (60)  ·  Metformin (52)  ·  Hydroxymethylglutaryl-CoA Reductase Inhibitors (51)  ·  Exercise (49)  ·  Niacin (48)  ·  Pravastatin (44)  ·  pitavastatin (41)  ·  Omacor (36)  ·  Diet (34)

Sponsors

AstraZeneca (131)  ·  Organon and Co (100)  ·  Takeda (72)  ·  Sanofi (67)  ·  Merck Sharp & Dohme LLC (59)  ·  Pfizer (53)  ·  Chong Kun Dang Pharmaceutical (50)  ·  National Heart, Lung, and Blood Institute (NHLBI) (49)  ·  Novartis Pharmaceuticals (46)  ·  Amgen (44)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (41)  ·  Genzyme, a Sanofi Company (37)  ·  Shire (34)  ·  Amicus Therapeutics (29)  ·  Regeneron Pharmaceuticals (27)

Countries

United States (1545)  ·  Canada (427)  ·  South Korea (299)  ·  China (298)  ·  United Kingdom (287)  ·  France (273)  ·  Germany (268)  ·  Italy (247)  ·  Spain (228)  ·  Netherlands (213)  ·  Australia (167)  ·  Brazil (146)  ·  Poland (140)  ·  Denmark (136)  ·  Czechia (128)

Top investigators

Forbes D Porter, M.D. (11)  ·  David JA Jenkins, MD, PhD, DSc (10)

Results publications

PMID 30183102, PMID 33078867, PMID 37994400, PMID 21518985, PMID 27777279, PMID 34298554, PMID 38018702, PMID 27657681, PMID 28181260, PMID 40587053, PMID 19793357, PMID 28304227, PMID 28324110, PMID 28964736, PMID 29685591, PMID 33990512, PMID 35277540, PMID 18783301, PMID 25614280, PMID 27578134, PMID 31194872, PMID 32609313, PMID 34677608, PMID 35916348, PMID 37565307, PMID 38063346, PMID 19744248, PMID 20136164, PMID 20573750, PMID 21586746, PMID 22301925, PMID 23661689, PMID 24239923, PMID 26872608, PMID 27206567, PMID 27659698, PMID 27839979, PMID 27888609, PMID 28391886, PMID 29037448, PMID 33332761, PMID 34617591, PMID 36279795, PMID 36520008, PMID 37624739, PMID 37658997, PMID 38504437, PMID 38757725, PMID 39847314, PMID 40525490

NIH funding

2015 (23), 2005 (22), 2023 (18), 2019 (12), 2025 (12), U54NS065768 (12), 2017 (11), 2016 (10), 2014 (9), 2018 (9), 2008 (8), 2009 (5), OT2HL158287 (5), R01HL168858 (3), 2004 (2)